Excess liver-related mortality among people with AIDS compared to the general population: an Italian nationwide cohort study using multiple causes of death.
AIDS
HIV
hepatic diseases
liver
liver cancer
multiple cause of death
standardized mortality ratio
Journal
HIV medicine
ISSN: 1468-1293
Titre abrégé: HIV Med
Pays: England
ID NLM: 100897392
Informations de publication
Date de publication:
11 2020
11 2020
Historique:
accepted:
11
07
2020
pubmed:
3
9
2020
medline:
24
11
2021
entrez:
3
9
2020
Statut:
ppublish
Résumé
Liver diseases have become a leading cause of death among people with AIDS (PWA). This study aimed to investigate whether PWA experienced excess mortality related to liver diseases as compared to the general population (non-PWA), using a multiple cause of death (MCoD; i.e. all conditions reported on death certificates) approach. A population-based, nationwide, retrospective cohort study was conducted among Italian people, aged 15-74 years, who had been diagnosed with AIDS since 2006. Date of death and MCoD data were retrieved, up to December 2015, by individual record linkage with national mortality data. Sex- and age-standardized mortality ratios (SMRs), with 95% confidence intervals (CIs), were estimated by dividing the observed number of deaths related to a specific condition among PWA to the expected number, based on non-PWA mortality rates. Among 7912 PWA (34 184 person-years), 2076 deaths occurred. The number of death certificates reporting liver diseases among MCoDs was 583 (28.1%), including 382 (18.4%) reporting viral hepatitis, 370 (17.8%) reporting nonviral liver diseases, and 41 (2.0%) reporting liver cancers. The corresponding SMRs were 40.4 (95% CI 37.2-43.8) for all liver diseases, 131.1 (95% CI 118.3-145.0) for viral hepatitis, 29.9 (95% CI 27.0-33.1) for nonviral liver diseases, and 11.2 (95% CI 8.1-15.3) for liver cancers. Particularly elevated SMRs emerged among PWA aged 15-49 years and those infected by injecting drug use. The high excess liver-related mortality observed among PWA warrants preventive actions to limit the burden of viral hepatitis coinfections, alcohol abuse, and metabolic disorders, especially among younger PWA and injecting drug users.
Types de publication
Comparative Study
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
642-649Informations de copyright
© 2020 British HIV Association.
Références
Antiretroviral Therapy Cohort Collaboration. Causes of death in HIV-1-infected patients treated with antiretroviral therapy, 1996-2006: collaborative analysis of 13 HIV cohort studies. Clin Infect Dis 2010; 50: 1387-1396.
Helleberg M, Kronborg G, Larsen CS et al. Causes of death among Danish HIV patients compared with population controls in the period 1995-2008. Infection 2012; 40: 627-634.
Schwarcz SK, Vu A, Hsu LC et al. Changes in causes of death among persons with AIDS: San Francisco, California, 1996-2011. AIDS Patients Care 2014; 28: 517-523.
Smith CJ, Ryom L, Weber R et al. Trends in underlying causes of death in people with HIV from 1999 to 2011 (D:A:D): a multicohort collaboration. Lancet 2014; 384: 241-248.
Hernando V, Perez-Cachafeiro S, Lewden C et al. All-cause and liver-related mortality in HIV positive subjects compared to the general population: differences by HCV co-infection. J Hepatol 2012; 57: 743-751.
Rosenthal E, Roussillon C, Salmon-Céron D et al. Liver-related deaths in HIV-infected patients between 1995 and 2010 in France: the Mortavic 2010 study in collaboration with the Agence Nationale de Recherche sur le SIDA (ANRS) EN 20 Mortalité 2010 survey. HIV Med 2015; 16: 230-239.
Grande E, Zucchetto A, Suligoi B et al. Multiple cause-of-death data among people with AIDS in Italy: a nationwide cross-sectional study. Popul Health Metr 2017; 15: 19.
Croxford S, Kitching A, Desai S et al. Mortality and causes of death in people diagnosed with HIV in the era of highly active antiretroviral therapy compared with the general population: an analysis of a national observational cohort. Lancet Pub Health 2017; 2: e35-e46.
Pettit AC, Giganti MJ, Ingle SM et al. Increased non-AIDS mortality among persons with AIDS-defining events after antiretroviral therapy initiation. J Int AIDS Soc 2017; 21: e25031.
Bosh KA, Coyle JR, Hansen V et al. HIV and viral hepatitis coinfection analysis using surveillance data from 15 US states and two cities. Epidemiol Infect 2018; 146: 920-930.
Obel N, Omland LH, Kronborg G et al. Impact of non-HIV and HIV risk factors on survival in HIV-infected patients on HAART: a population-based nationwide cohort study. PLoS One 2011; 6: e22698.
Whiteside YO, Selik R, An Q et al. Comparison of rates of death having any death-certificate mention of heart, kidney or liver disease among persons diagnosed with HIV infection with those in the general US population, 2009-2011. Open AIDS J 2015; 9: 14-22.
Hessol NA, Ma D, Scheer S et al. Changing temporal trends in non-AIDS cancer mortality among people diagnosed with AIDS: San Francisco, California, 1996-2013. Cancer Epidemiol 2018; 52: 20-27.
World Health Organization, WHO. International Statistical Classification of Diseases and Related Health Problems. Tenth Revision (ICD-10). Fifth Edition, Geneva, WHO, 2016. Available at https://icd.who.int/browse10/Content/statichtml/ICD10Volume2_en_2016.pdf (accessed 6 August 2020).
Zucchetto A, Virdone S, Taborelli M et al. Non-AIDS-Defining cancer mortality: emerging patterns in the late HAART Era. J Acquir Immune Defic Syndr 2016; 73: 190-196.
Suligoi B, Virdone S, Taborelli M et al. Excess mortality related to circulatory system diseases and diabetes mellitus among Italian AIDS patients vs. non-AIDS population: a population-based cohort study using the multiple causes-of-death approach. BMC Infect Dis 2018; 18: 428.
Ancelle-Park R. Expanded European AIDS case definition. Lancet 1993; 341: 441.
Regine V, Pugliese L, Boros S et al. Aggiornamento delle nuove diagnosi di infezione da HIV e dei casi di AIDS in Italia al 31 dicembre 2017. Notiziario Istituto Superiore di Sanità 2018; 31 (9 Suppl. 1). Rome: Istituto Superiore di Sanità.
ISTAT. Vital statistics on causes of death. Available at: http://siqual.istat.it/SIQual/visualizza.do?id=5000131 (accessed 18 November 2019).
Dal Maso L, Braga C, Franceschi S. Methodology used for "software for automated linkage in Italy" (SALI). J Biomed Inform 2001; 34: 387-395.
Ulm K. A simple method to calculate the confidence interval of a standardized mortality ratio (SMR). Am J Epidemiol 1990; 131: 373-375.
Breslow NE, Day NE. Statistical Methods in Cancer Research, Volume II. The Design and Analysis of Cohort Studies. IARC Scientific Publications, 82 Lyon, France, International Agency for Research on Cancer, 1987: 65-76. https://publications.iarc.fr/Book-And-Report-Series/Iarc-Scientific-Publications/Statistical-Methods-In-Cancer-Research-Volume-II-The-Design-And-Analysis-Of-Cohort-Studies-1986.
Platt L, Easterbrook P, Gower E et al. Prevalence and burden of HCV co-infection in people living with HIV: a global systematic review and meta-analysis. Lancet Infect Dis 2016; 16: 797-808.
Fernández-Montero JV, Vispo E, Barreiro P et al. Hepatitis delta is a major determinant of liver decompensation events and death in HIV-infected patients. Clin Infect Dis 2014; 58: 1549-1553.
Thornton AC, Jose S, Bhagani S et al. Hepatitis B, hepatitis C, and mortality among HIV-positive individuals. AIDS 2017; 31: 2525-2532.
Suonpera E, Matthews R, Milinkovic A, Arenas-Pinto A. Risky Alcohol consumption and associated health behaviour among HIV-Positive and HIV-Negative patients in a UK sexual health and HIV clinic: a Cross-Sectional questionnaire study. AIDS Behav 2020; 24: 1717-1726.
Parashar S, Collins AB, Montaner JS et al. Reducing rates of preventable HIV/AIDS-associated mortality among people living with HIV who inject drugs. Curr Opin HIV AIDS 2016; 11: 507-513.
Ganesan M, Poluektova LY, Kharbanda KK et al. Human immunodeficiency virus and hepatotropic viruses co-morbidities as the inducers of liver injury progression. World J Gastroenterol 2019; 25: 398-410.
Cowell A, Shenoi SV, Kyriakides TC et al. Trends in hospital deaths among human immunodeficiency virus-infected patients during the antiretroviral therapy era, 1995 to 2011. J Hosp Med 2015; 10: 608-614.
Mohr R, Boesecke C, Dold L et al. Return-to-health effect of modern combined antiretroviral therapy potentially predisposes HIV patients to hepatic steatosis. Medicine 2018; 97: e0462.
Massoud O, Charlton M. Nonalcoholic fatty liver disease/nonalcoholic steatohepatitis and hepatocellular carcinoma. Clin Liver Dis 2018; 22: 201-211.
Maurice JB, Patel A, Scott AJ et al. Prevalence and risk factors of nonalcoholic fatty liver disease in HIV-monoinfection. AIDS 2017; 31: 1621-1632.
Van Welzen BJ, Mudrikova T, Idrissi AE et al. A review of non-alcoholic fatty liver disease in HIV-infected patients: the next big thing? Infect Dis Ther 2019; 8: 33-50.
Rockstroh JK, Mohr R, Behrens G et al. Liver fibrosis in HIV: which role does HIV itself, long-term drug toxicities and metabolic changes play? Curr Opin HIV AIDS 2014; 9: 365-370.
Wada N, Jacobson LP, Cohen M et al. Cause-specific mortality among HIV-infected individuals, by CD4+ cell count at HAART initiation, compared with HIV-uninfected individuals. AIDS 2014; 28: 257-265.
European Monitoring Centre for Drugs and Drug Addiction. Drug-Related Infectious Diseases in Europe: Update from the EMCDDA Expert Network. Luxembourg, Publications Office of the European Union, 2019. Available at http://www.emcdda.europa.eu/system/files/publications/11442/20192115_TD0219248ENN_PDF.pdf (accessed 6 August 2020).
Laut KG, Shepherd L, Gottfredsson M et al. Variation in antiretroviral treatment coverage and virological suppression among three HIV key populations. AIDS 2018; 32: 2807-2819.
Pinato DJ, Dalla Pria A, Sharma R et al. Hepatocellular carcinoma: an evolving challenge in viral hepatitis and HIV coinfection. AIDS 2017; 31: 603-611.
Hu J, Liu K, Luo J. HIV-HBV and HIV-HCV coinfection and liver cancer development. Cancer Treat Res 2019; 177: 231-250.
European Centre for Disease Prevention and Control. Public Health Guidance on HIV, Hepatitis B and C testing in the EU/EEA - An Integrated Approach. Stockholm, ECDC, 2018. Avaliable at: https://www.ecdc.europa.eu/sites/default/files/documents/hiv-hep-testing-guidance_0.pdf (accessed 6 August 2020).
Luzi A, Suligoi B (eds). Nuove Linee di indirizzo per lo screening e la diagnosi delle principali patologie infettive correlate all’uso di sostanze nei Servizi per le Dipendenze. Notiziario Istituto Superiore di Sanità 2017; 30 (12 Suppl. 1). Istituto Superiore di Sanità. Available at: http://old.iss.it/binary/publ/cont/LINEE_DI_INDIRIZZO_online.pdf (accessed 18 November 2019).
Amele S, Peters L, Sluzhynska M et al. Establishing a hepatitis C continuum of care among HIV/hepatitis C virus-coinfected individuals in EuroSIDA. HIV Med 2019; 20: 264-273.